Quantcast
Last updated on April 17, 2014 at 8:34 EDT

Latest Lymphoid leukemia Stories

2011-01-18 16:41:27

Cyndia Charfi, a Ph. D student in biology at Universit© du Qu©bec à Montr©al (UQAM), supported by her thesis supervisors, Professor Ó°ric Rassart, and Adjunct Professor Elsy Edouard, UQAM, Department of Biological Sciences and BIOMED Research Centre, made a major breakthrough in research on B-cell acute lymphocytic leukemia, a disease that occurs most commonly in children. She has successfully identified a gene that may facilitate the...

2010-10-23 01:39:35

Chronic lymphocytic leukemia (CLL) cells survive and thrive not just by their own innate wiles, but by also acquiring aid and support from host cells in their surrounding environment. In a paper published online this week in The Proceedings of National Academy of Sciences, an international team of researchers led by cancer specialists at the University of California San Diego School of Medicine and the Moores UCSD Cancer Center identify a particular relationship that can promote notably...

2010-09-23 09:30:00

BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the leukemia market will be driven mostly by chronic myelogenous leukemia (CML) therapies (Novartis's Gleevec and Tasigna and Bristol-Myers Squibb's Sprycel) and chronic lymphocytic leukemia (CLL) therapies (Biogen Idec/Roche's Rituxan and Cephalon's Treanda) until 2015, when patent and orphan-drug...

2010-09-16 15:24:00

LOS ANGELES, Sept. 16 /PRNewswire/ -- Film and stage legend Mel Brooks will lend his comic genius and storied career to a good cause for a one night only event to benefit The Leukemia & Lymphoma Society (LLS). Brooks will be joined by BBC Creative Director Alan Yentob, a longtime friend of the comedian, who will moderate the discussion. The two men have been close friends ever since Yentob made a documentary for the old BBC Arena programme "I thought I was taller - a short history of...

2010-08-30 08:00:00

BURLINGTON, Mass., Aug. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit...

2010-07-12 10:25:00

WHITE PLAINS, N.Y., July 12 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded two new grants through its prestigious Marshall A. Lichtman Specialized Center of Research (SCOR) research initiative, bringing the program's total funding to $210.5 million since its inception in 2000. Both recipients have long-time connections to LLS. They are John C. Byrd, M.D., Associate Director for Translational Research, The Ohio State University Comprehensive...

2010-02-02 09:25:00

WHITE PLAINS, N.Y., Feb. 2 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is pleased to announce that, effective Feb. 1, 2010, patients with myeloma and waldenstrom macroglobulinemia will now be able to receive up to $10,000 in support to help offset the costs of prescription drug co-pays and other insurance related expenses. Prior to this change, the maximum benefit for myeloma and waldenstrom macroglobulinemia patients was $5,000. Patients, caregivers and healthcare...

2009-11-06 14:46:00

WHITE PLAINS, N.Y., Nov. 6 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) will again be participating in Gap Inc.'s Give & Get program, which in its first two campaigns this past spring and summer, garnered more than $1 million to support LLS's blood cancer research funding and patient education and support services. During the campaign, taking place from November 12th to 15th, Gap Inc. will issue downloadable 30% discount coupons participants can use (in-store only) at all...

2009-10-08 07:30:00

NEW YORK, Oct. 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 2 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). This Phase 2 study was designed by Daphne Friedman, MD, Instructor and Principal Investigator, in coordination with J. Brice Weinberg, Professor, and Mark Lanasa, Assistant Professor,...

2009-04-25 08:17:16

Pre-clinical study shows 50 percent reduced tumor cell burden Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered how to turn off a certain receptor that promotes the growth of leukemia cells. The pre-clinical study was presented yesterday in a platform session at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology (ASPHO). "There is a certain receptor we now know is expressed in acute myeloid...